The Amyloidosis Channel on VJHemOnc is an independent medical education platform, supported with funding from Prothena (Silver). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ISA 2024 | Results of the MoRBiDA trial: 18F-PET for the detection of cardiac involvement in AL amyloidosis
Paolo Milani, MD, PhD, Amyloidosis Research and Treatment Center, Pavia, Italy, discusses the ongoing MoRBIDA trial (NCT04392960) testing the role of 18F-PET in patients with newly diagnosed light chain (AL) amyloidosis. The study aims to combine 18F-PET with echocardiography and cardiac MRI. Initial results indicate that 18F-PET effectively identifies cardiac involvement in most cases, though some protocol adjustments may be needed. This interview took place at the XIX International Symposium on Amyloidosis (ISA) in Rochester, MN.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
Honoraria: Pfizer, Jannsen-Cilag
Membership on Board of Directors or advisory committee: Jannsen-Cilag, Siemens
